Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis

被引:54
作者
Goubau, C. [1 ]
Wilschanski, M. [2 ]
Skalicka, V. [3 ]
Lebecque, P. [4 ]
Southern, K. W. [5 ]
Sermet, I. [6 ]
Munck, A. [7 ]
Derichs, N. [8 ]
Middleton, P. G. [9 ,10 ]
Hjelte, L. [11 ]
Padoan, R. [12 ]
Vasar, M. [13 ]
De Boeck, K. [1 ]
机构
[1] Univ Louvain, Dept Paediat, Louvain, Belgium
[2] Hadassah Med Org, Dept Paediat Gastroenterol, Jerusalem, Israel
[3] Fac Hosp Motol, Dept Paediat, Prague, Czech Republic
[4] Catholic Univ Louvain, Clin St Luc, B-1200 Brussels, Belgium
[5] Royal Liverpool Childrens Hosp, Liverpool L7 7DG, Merseyside, England
[6] Hop Necker Enfants Malad, Paris, France
[7] Hop Robert Debre, F-75019 Paris, France
[8] Hannover Med Sch, Dept Paediat, D-30623 Hannover, Germany
[9] Westmead Hosp, Ludwig Engel Ctr Resp Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia
[10] Univ Sydney, Westmead, NSW 2145, Australia
[11] Karolinska Univ, Huddinge Hosp, Stockholm CF Ctr, Karolinska Inst, Stockholm, Sweden
[12] Osped Bambini Brescia, CF Ctr, Brescia, Italy
[13] Tartu Univ Clin, Childrens Clin, Tartu, Estonia
关键词
NASAL POTENTIAL DIFFERENCE; TRANSMEMBRANE REGULATOR GENE; PULMONARY-FUNCTION; DISEASE; CONSENSUS; MUTATIONS; EXACERBATIONS; GENOTYPE; LIVER;
D O I
10.1136/thx.2008.104752
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF. Methods: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI). Results: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups. Conclusion: Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.
引用
收藏
页码:683 / 691
页数:9
相关论文
共 42 条
[1]   Exacerbations in cystic fibrosis:: 2 • Prevention [J].
Bell, Scott C. ;
Robinson, Philip J. .
THORAX, 2007, 62 (08) :723-732
[2]   Nonclassic cystic fibrosis and CFTR-related diseases [J].
Boyle, MP .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :498-503
[3]   Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice [J].
Castellani, C. ;
Cuppens, H. ;
Macek, M., Jr. ;
Cassinian, J. J. ;
Kerern, E. ;
Durie, P. ;
Tullis, E. ;
Assael, B. M. ;
Bombieri, C. ;
Brown, A. ;
Casals, T. ;
Claustres, M. ;
Cutting, G. R. ;
Dequeker, E. ;
Dodge, J. ;
Doull, I. ;
Farrell, P. ;
Ferec, C. ;
Girodon, E. ;
Johannesson, M. ;
Kerem, B. ;
Knowles, M. ;
Munck, A. ;
Pignatti, P. F. ;
Radojkovic, D. ;
Rizzotti, P. ;
Schwarz, M. ;
Stuhnnann, M. ;
Tzetis, M. ;
Zielenski, J. ;
Elborn, J. S. .
JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) :179-196
[4]  
Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO
[5]  
2-L
[6]   ANALYSIS OF RISK-FACTORS FOR THE DEVELOPMENT OF LIVER-DISEASE ASSOCIATED WITH CYSTIC-FIBROSIS [J].
COLOMBO, C ;
APOSTOLO, MG ;
FERRARI, M ;
SEIA, M ;
GENONI, S ;
GIUNTA, A ;
SERENI, LP .
JOURNAL OF PEDIATRICS, 1994, 124 (03) :393-399
[7]   Late CF caused by homozygous IVS8-5T CFTR polymorphism [J].
Cottin, V ;
Thibout, Y ;
Bey-Omar, F ;
Durieu, I ;
Laoust, L ;
Morel, Y ;
Cordier, JF .
THORAX, 2005, 60 (11) :974-975
[8]   Cystic fibrosis: terminology and diagnostic algorithms [J].
De Boeck, K. ;
Wilschanski, M. ;
Castellani, C. ;
Taylor, C. ;
Cuppens, H. ;
Dodge, J. ;
Sinaasappel, M. .
THORAX, 2006, 61 (07) :627-635
[9]   Pancreatitis among patients with cystic fibrosis: Correlation with pancreatic status and genotype [J].
De Boeck, K ;
Weren, M ;
Proesmans, M ;
Kerem, E .
PEDIATRICS, 2005, 115 (04) :e463-e469
[10]   Genotype-phenotype correlation for pulmonary function in cystic fibrosis [J].
de Gracia, J ;
Mata, F ;
Alvarez, A ;
Casals, T ;
Gatner, S ;
Vendrell, M ;
de la Rosa, D ;
Guarner, L ;
Hermosilla, E .
THORAX, 2005, 60 (07) :558-563